Four Anti-dsDNA Antibody Assays in Relation to Systemic Lupus Erythematosus Disease Specificity and Activity
Authors:
- Helena EnocssonHEHelena Enocsson
- Christopher SjöwallChristopher Sjöwall
- Lina WirestamLWLina Wirestam
- Charlotte DahleCDCharlotte Dahle
- Alf KastbomAKAlf Kastbom
- Johan RönnelidJRJohan Rönnelid
- Jonas WetteröJWJonas Wetterö
- Thomas SkoghTSThomas Skogh
- 15 February 2015
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 42 (5) , 817-825
Abstract
Objective.: Analysis of antibodies against dsDNA is an important diagnostic tool for systemic lupus erythematosus (SLE), and changes in anti-dsDNA antibody levels are also used to assess disease activity. Herein, 4 assays were compared with regard to SLE specificity, sensitivity, and association with disease activity variables.Methods.: Cross-sectional sera from 178 patients with SLE, of which 11 were followed consecutively, from a regional Swedish SLE register were analyzed for immunoglobulin G (IgG) anti-dsDNA by bead-based multiplex assay (FIDIS; Theradig), fluoroenzyme-immunoassay (EliA; Phadia/Thermo Fisher Scientific), Crithidia luciliae immunofluorescence test (CLIFT; ImmunoConcepts), and line blot (EUROLINE; Euroimmun). All patients with SLE fulfilled the 1982 American College of Rheumatology and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC-12) classification criteria. Healthy individuals (n = 100), patients with rheumatoid arthritis (n = 95), and patients with primary Sjögren syndrome (n = 54) served as controls.Results.: CLIFT had the highest SLE specificity (98%) whereas EliA had the highest sensitivity (35%). When cutoff levels for FIDIS, EliA, and EUROLINE were adjusted according to SLICC-12 (i.e., double the reference limit when using ELISA), the specificity and sensitivity of FIDIS was comparable to CLIFT. FIDIS and CLIFT also showed the highest concordance (84%). FIDIS performed best regarding association with disease activity in cross-sectional and consecutive samples. Fisher’s exact test revealed striking differences between methods regarding associations with certain disease phenotypes.Conclusion.: CLIFT remains a good choice for diagnostic purposes, but FIDIS performs equally well when the cutoff is adjusted according to SLICC-12. Based on results from cross-sectional and consecutive analyses, FIDIS can also be recommended to monitor disease activity.Keywords
This publication has 32 references indexed in Scilit:
- Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish registerBMJ Open, 2013
- Anti-dsDNA Antibody Isotypes in Systemic Lupus Erythematosus: IgA in Addition to IgG Anti-dsDNA Help to Identify Glomerulonephritis and Active DiseasePLOS ONE, 2013
- Autoantibodies predate the onset of systemic lupus erythematosus in northern SwedenArthritis Research & Therapy, 2011
- Interferon‐α mediates suppression of C‐reactive protein: Explanation for muted C‐reactive protein response in lupus flares?Arthritis & Rheumatism, 2009
- A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus--a retrospective review of casesRheumatology, 2007
- Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversityAnnals of the Rheumatic Diseases, 2004
- Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals of the Rheumatic Diseases, 2002
- Frequency and Significance of Antibodies to Actin in Type 1 Autoimmune HepatitisHepatology, 1996
- Immunopathologic Studies of Systemic Lupus Erythematosus. II. Antinuclear Reaction of γ-Globulin Eluted from Homogenates and Isolated Glomeruli of Kidneys from Patients with Lupus Nephritis *Journal of Clinical Investigation, 1967
- Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus.Journal of Clinical Investigation, 1966